respiratori
syncyti
viru
rsv
first
isol
chimpanze
suffer
respiratori
ill
walter
reed
armi
institut
research
unit
follow
year
viru
also
isol
infant
sever
lower
respiratori
sinc
rsv
demonstr
ubiquit
pathogen
infect
nearli
children
year
age
onehalf
experienc
two
infect
global
rsv
respons
inhospit
death
annual
children
younger
year
unit
state
rsv
diseas
burden
similar
nonpandem
influenza
elderli
highrisk
recognit
substanti
diseas
burden
attribut
rsv
ignit
interest
develop
effect
intervent
led
substanti
invest
pharmaceut
compani
philanthrop
organ
rsv
filament
envelop
negativesens
singlestrand
rna
viru
belong
orthopneumoviru
genu
pneumovirida
famili
order
mononegaviral
famili
also
contain
human
metapneumoviru
hmpv
belong
metapneumoviru
genu
like
rsv
major
pathogen
symptom
rsv
hmpv
infect
gener
transmit
close
although
spread
aerosol
short
period
replic
epitheli
line
nasopharynx
upper
respiratori
tract
rsv
infect
may
spread
small
bronchiol
alveoli
lower
respiratori
host
immun
respons
rsv
infect
increas
mucu
product
inflamm
lead
narrow
airway
result
bronchiol
young
children
acut
respiratori
ill
older
adult
underli
chronic
seri
clinic
trial
aberr
immun
respons
natur
infect
immun
formalininactiv
wholeviru
rsv
vaccin
shown
caus
vaccineenhanc
diseas
diseas
character
part
pulmonari
neutrophil
immun
complex
deposit
small
result
trial
rsv
vaccin
develop
progress
cautious
particularli
rsvnaiv
infant
current
licens
vaccin
rsv
past
year
tremend
effort
differ
vaccin
candid
clinic
preclin
develop
multipl
vaccin
target
popul
pregnant
women
elderli
individu
rsvnaiv
infant
like
benefit
specif
vaccin
modal
regimen
legaci
vaccineenhanc
diseas
part
led
develop
altern
intervent
use
monoclon
antibodi
small
molecul
set
altern
includ
fdaapprov
monoclonalantibodi
therapi
licens
brand
name
synagi
also
known
palivizumab
howev
use
restrict
passiv
immunoprophylaxi
highrisk
infant
owe
cost
modest
potent
neutral
antibodi
longer
halfliv
develop
like
antibodi
smallmolecul
fusion
inhibitor
block
rsv
entri
avoid
concern
relat
enhanc
diseas
upon
natur
infect
review
briefli
describ
structur
rsv
virion
infecti
cycl
focu
recent
progress
made
understand
entri
rsv
host
cell
discuss
remain
unansw
question
also
highlight
recent
advanc
effort
combat
rsv
infect
includ
develop
vaccin
monoclon
antibodi
smallmolecul
fusion
inhibitor
conclud
perspect
next
year
may
hold
rsv
research
clinic
intervent
rsv
genom
kb
contain
gene
encod
protein
fig
gene
two
overlap
orf
gener
transcript
process
factor
protein
govern
switch
transcript
genom
replic
first
two
transcrib
gene
nonstructur
protein
togeth
inhibit
interferon
major
differ
genom
orthopneumoviru
metapneumoviru
genera
absenc
two
gene
virus
belong
latter
rsv
virion
contain
lipid
bilay
display
fusion
f
attach
g
small
hydrophob
sh
protein
fig
f
g
protein
greater
abund
sh
protein
pentamer
ion
channel
thought
involv
delay
apoptosi
infect
viral
envelop
support
layer
matrix
protein
protein
nonglycosyl
structur
protein
line
inner
leaflet
viral
envelop
associ
cytoplasm
domain
f
mediat
associ
enclos
ribonucleoprotein
complex
rnp
compris
viral
genom
rna
tightli
associ
nucleoprotein
n
also
associ
rnp
rnadepend
rna
polymeras
complex
rdrp
compos
larg
polymeras
subunit
l
phosphoprotein
polymeras
cofactor
p
n
g
protein
produc
infect
cell
either
fulllength
membranebound
form
respons
viral
secret
isoform
sg
mediat
immun
fig
fulllength
g
protein
singlepass
type
ii
integr
membran
protein
synthes
although
exact
length
vari
strain
aminotermin
cytosol
domain
contain
singl
unpair
cystein
adjac
transmembran
domain
posttransl
ectodomain
consist
two
larg
sequencevari
mucinlik
domain
flank
central
conserv
region
heparinbind
domain
fig
mucinlik
domain
predict
disord
contain
amino
acid
composit
serin
threonin
residu
prolin
g
protein
ectodomain
posttransl
modifi
nlink
glycan
olink
glycan
constitut
molecular
mass
matur
depend
produc
cell
differ
molecular
mass
oligomer
form
g
sg
form
aris
owe
translat
initi
altern
aug
codon
fulllength
g
protein
encod
locat
middl
transmembran
subsequ
proteolyt
event
remov
remain
portion
transmembran
domain
enabl
ectodomain
secret
fig
sg
demonstr
act
antigen
decoy
gdirect
antibodi
decreas
fcmediat
antivir
activ
although
may
role
yet
discov
thorough
understand
sg
function
could
particularli
import
develop
passiv
administ
gdirect
monoclon
antibodi
sequenc
central
conserv
region
straindepend
variat
yet
contain
strictli
conserv
amino
acid
partial
overlap
cystin
noos
domain
reason
strict
conserv
residu
remain
unknown
cystin
noos
contain
four
cystein
form
two
disulfid
bond
third
fourth
cystein
arrang
form
motif
structur
synthet
peptid
deriv
central
region
bovin
rsv
g
human
rsv
g
respect
determin
nmr
cystin
noos
present
structur
adopt
conserv
fold
also
observ
fourth
subdomain
tumour
necrosi
factor
receptor
tnfr
past
year
two
group
determin
four
highresolut
xray
crystal
structur
neutral
antibodi
bound
human
rsv
gderiv
although
cystin
noos
structur
conserv
minor
flexibl
tip
noos
multipl
conform
highli
conserv
aminotermin
flank
region
observ
suggest
region
flexibl
gener
unstructur
fig
g
protein
variabl
structur
protein
among
rsv
isol
sequenc
use
numer
epidemiolog
evolutionari
studi
review
variabl
primarili
local
mucinlik
domain
dictat
rsv
antigen
group
term
rsva
rsvb
group
also
refer
subtyp
subgroup
origin
rsv
serolog
studi
identifi
singl
serotyp
two
distinct
antigen
annual
epidem
rsv
strain
differ
group
commonli
cocircul
group
rsva
virus
predomin
past
year
duplic
event
rsv
g
ectodomain
gener
emerg
rsv
genotyp
detect
global
includ
bueno
air
genotyp
ba
ontario
genotyp
ba
genotyp
distinct
rsvb
genotyp
duplic
arrang
tandem
repeat
insert
second
mucinlik
domain
near
carboxyl
follow
first
isol
ba
genotyp
spread
global
replac
circul
rsvb
strain
certain
genotyp
distinct
ancestr
rsva
genotyp
tandem
repeat
insert
carboxytermin
mucinlik
genotyp
spread
diversifi
global
even
rapid
rate
ba
rapid
global
spread
emerg
genotyp
suggest
duplic
event
provid
select
advantag
may
due
increas
viral
steric
mask
f
glycoprotein
neutral
anoth
mechan
yet
determin
rsv
f
protein
class
viral
fusion
glycoprotein
share
structur
similar
paramyxovirida
f
despit
limit
sequenc
similar
rsv
f
synthes
polypeptid
call
posttransl
modifi
nlink
glycan
depend
becom
fusion
compet
f
must
cleav
two
polybas
site
separ
amino
acid
peptid
contain
nlink
fig
prime
event
perform
furinlik
host
transgolgi
network
f
transport
plasma
proteolysi
gener
two
subunit
aminotermin
subunit
residu
carboxytermin
subunit
residu
glycosyl
form
approxim
kda
kda
respect
subunit
coval
link
two
disulfid
bond
yield
heterodimer
three
associ
form
matur
trimer
form
f
protein
although
yet
confirm
evid
suggest
trimer
rsv
f
occur
proteolyt
would
contrast
class
viral
fusion
protein
includ
envelop
env
coronaviru
spike
even
paramyxoviru
f
cleav
trimer
f
adopt
prefus
conform
spheroid
shape
reach
nm
viral
fig
fusion
peptid
locat
amino
termini
subunit
buri
insid
central
caviti
protein
prefus
conform
f
unstabl
low
energi
barrier
refold
evidenc
accumul
refold
postfus
form
protein
surfac
virion
function
refold
process
fusion
peptid
withdrawn
central
caviti
project
away
viral
membran
secondari
structur
element
subunit
refold
long
fig
anoth
membran
host
cell
membran
close
proxim
fusion
peptid
insert
membran
f
protein
span
membran
conform
f
refer
hypothet
prehairpin
intermedi
part
observ
indirectli
f
protein
parainfluenza
type
f
protein
continu
refold
heptad
repeat
pattern
amino
termini
carboxyl
termini
subunit
associ
form
trimer
hairpin
bring
two
membran
togeth
facilit
refold
process
irrevers
postfus
conform
f
stand
nm
extrem
stabl
melt
temperatur
differ
free
energi
prefus
postfus
conform
offset
free
energi
need
deform
fuse
two
appos
membran
although
number
f
protein
requir
form
fusion
pore
determin
unlik
g
protein
sequenc
f
ectodomain
differ
rsva
rsvb
lack
sequenc
variat
f
explain
singl
rsv
serotyp
stark
contrast
sequenc
variat
observ
class
viral
fusion
protein
env
influenza
viru
haemagglutinin
ha
thu
rsv
f
undergo
substanti
antigen
drift
immuneevas
strategi
despit
elicit
neutral
antibodi
peopl
infect
consequ
vaccin
rsv
may
easier
obtain
vaccin
univers
influenza
vaccin
primari
role
g
protein
attach
virion
cell
surfac
interact
host
cell
attach
factor
g
protein
shown
bind
glycosaminoglycan
gag
unbranch
disaccharid
polym
link
transmembran
protein
surfac
mani
mammalian
cell
interact
primarili
mediat
stretch
posit
charg
amino
acid
locat
two
mucinlik
domain
g
refer
heparinbind
howev
variant
g
lack
heparinbind
domain
retain
heparinasesensit
bind
cell
suggest
region
g
may
bind
weakli
neg
charg
region
heparan
sulfat
consid
primari
attach
although
iduronicacidcontain
gag
may
contribut
lesser
howev
conflict
report
abund
heparan
sulfat
apic
surfac
ciliat
welldifferenti
human
airway
epitheli
princip
site
rsv
replic
natur
thu
although
gag
mediat
interact
g
surfac
immort
cell
interact
may
physiolog
anoth
host
cell
attach
factor
thought
interact
g
fractalkin
receptor
receptor
analysi
amino
acid
sequenc
g
identifi
motif
also
found
chemokin
fractalkin
natur
ligand
like
g
fractalkin
tether
membran
mucinlik
domain
found
solubl
protein
due
variou
line
investig
immort
human
airway
epitheli
cell
includ
flow
cytometri
fluoresc
microscopi
chemotaxi
rsv
infect
suggest
interact
g
mediat
motif
cystin
howev
direct
interact
use
purifi
compon
demonstr
moreov
structur
fractalkin
g
cystin
noos
adopt
disulfidebond
arrang
fractalkin
differ
g
thu
precis
role
rsv
entri
remain
defin
although
g
facilit
attach
virion
host
cell
surfac
rsv
variant
lack
g
sh
grow
well
cell
impli
role
f
protein
attach
like
g
f
protein
demonstr
interact
immobil
heparin
cellular
heparan
sulfat
promot
attach
infect
immort
virion
contain
f
surfac
retain
infect
cell
treat
heparinas
defici
gag
synthesi
suggest
f
also
interact
one
nongag
attach
factor
sever
protein
propos
interact
f
facilit
rsv
entri
includ
intercellular
adhes
molecul
epiderm
growth
factor
receptor
egfr
data
nucleolin
strongest
nucleolin
shown
interact
mani
virus
includ
parainfluenza
type
enteroviru
haemorrhag
fever
adenoassoci
viru
type
given
promiscu
nucleolin
like
function
attach
factor
rsv
f
oppos
act
function
receptor
also
note
put
attach
factor
none
demonstr
biochem
biophys
interact
directli
f
use
purifi
compon
attach
fusion
viral
host
cell
membran
must
occur
rnp
enter
cytoplasm
basi
experi
demonstr
fusion
phindepend
insensit
lysosom
rsvinfect
cell
fuse
neighbour
cell
membran
gener
multinucl
cell
call
rsv
fusion
thought
occur
plasma
membran
howev
interpret
assum
virus
util
endocyt
pathway
fusion
requir
low
ph
infecti
entri
sinc
initi
rsv
fusion
experi
varieti
mechan
viral
endocyt
entri
defin
phindepend
requir
low
ph
activ
endosom
proteas
review
recent
report
indic
initi
step
rsv
fusion
occur
cholesterolrich
microdomain
plasma
membran
complet
membran
fusion
possibl
requir
dynaminindepend
endocyt
subsequ
studi
demonstr
rsv
util
macropinocytosi
initi
entri
mechan
follow
fusion
thu
evid
suggest
either
twostep
fusion
event
fusion
endosom
macropinocytosi
howev
may
case
rsv
fuse
plasma
membran
endocyt
vesicl
differ
effici
depend
environment
condit
target
cell
although
question
remain
locat
rsv
fusion
even
less
known
event
initi
trigger
fusion
class
viral
fusion
protein
three
trigger
well
defin
low
ph
case
influenza
viru
ha
direct
receptor
bind
use
env
provoc
second
viral
glycoprotein
mechan
paramyxoviru
f
protein
box
mention
substanti
evid
support
phindepend
trigger
rsv
f
receptorinduc
trigger
remain
possibl
although
host
cell
molecul
stimul
refold
f
identifi
date
evid
molecul
suggest
articl
report
human
rsv
infect
human
bovin
primari
cell
wherea
bovin
rsv
infect
bovin
human
primari
use
chimer
virus
speci
tropism
attribut
subunit
howev
knowledg
data
neither
pursu
independ
verifi
third
option
provoc
second
viral
glycoprotein
appear
unlik
given
virion
lack
g
sh
protein
infecti
grow
high
titr
cultur
furthermor
unlik
attach
protein
paramyxovirus
tertiari
quaternari
g
protein
rsv
relat
hmpv
predict
mostli
lack
structur
would
make
difficult
transduc
bind
event
g
protein
f
protein
fourth
mechan
origin
propos
certain
paramyxovirus
known
clamp
model
review
wherebi
g
protein
bind
prevent
spontan
trigger
f
protein
engag
g
protein
host
cell
receptor
abil
virus
lack
g
protein
grow
high
titr
cell
cultur
disfavour
mechan
rsv
f
altern
hypothesi
rsv
lack
spatiotempor
control
f
protein
trigger
benefit
trigger
proper
time
place
fusion
protein
remain
function
possibl
product
fusion
event
maxim
howev
may
necessari
virus
effici
well
document
prefus
conform
rsv
f
unstabl
convert
postfus
form
basal
expect
longer
incub
time
incub
elev
temperatur
increas
convers
postfus
therefor
possibl
basal
rate
spontan
convers
postfus
form
suffici
rsv
entri
attach
g
f
bring
target
cell
membran
close
apposit
refold
f
protein
fig
evid
model
would
like
requir
fusion
reconstitut
experi
liposom
support
lipid
bilay
composit
target
membran
could
care
control
high
level
rsvneutralizingantibodi
titr
correl
protect
children
adult
includ
elderli
rsv
intraven
immun
globulin
infus
prepar
respigam
use
prophylact
late
earli
prevent
sever
rsvassoci
lower
respiratori
tract
diseas
young
children
bronchopulmonari
dysplasia
prematur
use
respigam
discontinu
replac
prophylaxi
palivizumab
synagi
human
murin
monoclon
antibodi
bind
f
palivizumab
recogn
epitop
within
antigen
site
ii
preserv
prefus
postfus
f
fig
palivizumab
prevent
trigger
conform
chang
f
presum
block
entri
membran
fusion
prevent
convers
prehairpin
intermedi
postfus
conform
respigam
palivizumab
use
prophylaxi
highrisk
infant
cost
limit
result
tremend
advanc
monoclonalantibodyisol
technolog
past
year
hundr
humanderiv
antibodi
direct
rsv
f
g
protein
isol
fdirect
antibodi
potent
palivizumab
mani
recogn
epitop
locat
exclus
prefus
conform
consequ
prefusionspecif
antibodi
abl
lock
f
prefus
conform
prevent
convers
prehairpin
one
human
antibodi
call
recogn
antigen
site
optim
produc
variant
enhanc
potenc
extend
serum
owe
improv
may
requir
singl
dose
rsv
season
prevent
sever
diseas
infant
result
phase
iib
clinic
studi
expect
late
howev
differ
prefusionspecif
antibodi
recogn
antigen
site
v
recent
fail
reach
clinic
end
point
phase
iii
reason
failur
yet
known
prefusionspecif
antibodi
also
preclin
develop
antibodi
direct
g
protein
inhibit
viral
cocktail
antibodi
f
g
two
differ
antigen
site
f
also
consid
may
lead
synergist
effect
reduc
viral
escap
phenotyp
screen
target
chemic
librari
identifi
sever
structur
distinct
molecul
inhibit
rsv
fusion
target
cell
review
basi
crosslink
studi
rsv
biochem
structur
studi
peptid
compris
heptad
repeat
rsv
thought
small
molecul
bound
fusion
intermedi
f
prevent
postfus
conform
complet
form
howev
prefus
postfus
f
protein
crystal
structur
determin
escap
mutat
molecul
found
cluster
insid
central
caviti
prefus
conform
wherea
postfus
conform
separ
fig
crystallograph
experi
later
reveal
small
molecul
bind
insid
central
caviti
prefus
conform
interact
residu
fusion
peptid
second
heptad
function
studi
solubl
f
membranebound
f
demonstr
small
molecul
function
antagonist
prevent
trigger
prefus
conform
date
known
rsv
smallmolecul
fusion
inhibitor
bind
pocket
mechan
action
fig
fusion
inhibitor
presatovir
develop
gilead
scienc
janssen
pharmaceut
respect
perform
well
phase
ii
doubleblind
placebocontrol
humanchalleng
studi
oral
administr
either
compound
led
reduct
viral
load
diseas
sever
among
healthi
adult
experiment
infect
intranas
clinic
isol
particip
administ
fusion
inhibitor
either
day
inocul
time
posit
test
rsv
demonstr
compound
could
use
treatment
upper
respiratori
tract
infect
administ
soon
infect
cours
protect
lower
respiratori
tract
infant
naturalinfect
set
like
prove
difficult
proofofprincipl
adult
challeng
studi
describ
fusion
inhibitor
need
evalu
paediatr
popul
concern
rsv
fusion
inhibitor
eas
escap
variant
f
protein
aris
cell
cultur
mani
variant
howev
reduc
fit
cell
cultur
growth
assay
reach
titr
approxim
lower
wildtyp
viru
hour
present
degre
escap
variant
may
aris
human
treat
fusion
inhibitor
unknown
effect
emerg
variant
would
clinic
outcom
highresolut
structur
inform
avail
mani
compound
may
possibl
design
nextgener
inhibitor
resist
escap
bind
differ
site
f
protein
cocktail
fusion
inhibitor
could
use
suppress
outgrowth
escap
variant
better
understand
mechan
escap
fusion
inhibitor
would
also
aid
effort
rsv
vaccin
develop
becom
sophist
owe
recent
advanc
understand
structur
function
viral
protein
morpholog
architectur
virion
immun
respons
natur
infect
caus
vaccineenhanc
diseas
advanc
creat
complex
vaccin
landscap
candid
clinic
preclin
develop
compris
six
differ
vaccin
modal
target
one
three
major
target
popul
review
particlebas
subunitbas
vaccin
intend
elderli
peopl
matern
immun
owe
concern
vaccin
may
caus
vaccineenhanc
diseas
rsvnaiv
infant
f
protein
primari
antigen
modal
although
viruslik
particl
also
contain
g
protein
subunitbas
vaccin
consist
g
protein
approxim
year
ago
research
demonstr
major
rsvneutral
activ
human
sera
specif
prefus
conform
mani
potent
antibodi
specif
target
result
vaccin
develop
candid
contain
f
protein
focus
structurebas
engin
approach
stabil
f
prefus
anim
studi
shown
prefus
f
elicit
higher
neutral
antibodi
titr
postfus
f
current
sever
prefus
fsubunit
vaccin
candid
phase
clinic
result
expect
announc
candid
contain
postfus
f
molecul
postfus
f
morpholog
fail
sever
recent
latestag
clinic
remain
develop
one
candid
test
phase
iii
particlebas
subunitbas
vaccin
intend
elderli
individu
matern
immun
challeng
induc
antibodi
respons
suffici
titr
durat
protect
elderli
peopl
newborn
sever
diseas
rsv
season
liveattenu
chimer
viru
vaccin
primarili
intend
paediatr
popul
consid
safe
rsvnaiv
infant
given
demonstr
inabl
prime
vaccineenhanc
diseas
review
vaccin
base
viral
vector
dna
rna
also
thought
safe
infant
infant
cell
produc
encod
antigen
antigen
lead
balanc
cell
respons
display
properli
fold
antigen
cell
surfac
antibodi
recognit
elicit
sever
liveattenu
vaccin
candid
phase
trial
major
attenu
via
delet
viral
gene
new
candid
preclin
develop
includ
engin
display
prefusionstabil
variant
f
three
vectorbas
candid
almost
complet
phase
ii
trial
includ
two
adenoviru
candid
express
either
prefusionstabil
f
f
n
modifi
vaccinia
ankara
mva
candid
express
f
g
n
liveattenu
vaccin
achiev
optim
balanc
attenu
immunogen
crucial
wherea
viral
vector
nucleicacidbas
vaccin
need
achiev
suffici
gene
deliveri
express
produc
robust
immun
respons
substanti
progress
understand
rsv
entri
although
basic
scienc
continu
lag
behind
clinic
advanc
inde
may
closer
effect
rsv
vaccin
understand
molecular
mechan
rsv
attach
fusion
futur
experi
defin
g
protein
interact
uncov
new
host
cell
attach
factor
similarli
interact
f
g
protein
host
cell
factor
need
biochem
biophys
character
develop
reconstitut
fusion
assay
help
better
defin
minim
requir
rsv
fusion
answer
outstand
question
concern
trigger
f
protein
structur
studi
f
protein
intermedi
well
uncleav
form
f
also
improv
understand
rsv
fusion
may
identifi
new
target
antibodi
small
molecul
next
year
excit
time
clinic
intervent
outcom
clinic
eagerli
anticip
result
clinic
trial
involv
vaccin
contain
prefus
postfus
f
antigen
clinic
trial
fusion
inhibitor
ongo
new
trial
start
soon
smallmolecul
monoclonalantibodi
intervent
bind
singl
site
glycoprotein
presenc
distribut
natur
occur
rsv
variant
need
monitor
could
affect
result
clinic
trial
longterm
product
efficaci
similarli
largescal
administr
intervent
may
select
emerg
escap
variant
occur
rna
virus
influenza
viru
cocktail
one
antibodi
small
molecul
consid
develop
vaccin
may
also
benefit
monitor
rsv
variat
although
gener
immun
respons
vaccin
divers
target
multipl
viral
epitop
hope
current
optim
surround
rsv
intervent
well
found
one
effect
intervent
licens
next
decad
advanc
would
tremend
impact
live
mani
world
vulner
popul
